Mopetia (Paliperidone)

Paliperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain. This dual antagonism balances dopaminergic and serotonergic activity, decreasing the over‑activity that contributes to psychotic symptoms while also addressing negative and mood‑related aspects of the disorders.

The appropriate dose of Mopetia is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage regimens are not publicly disclosed and should be obtained from the treating healthcare professional.

Safety data for paliperidone in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss individual circumstances and consider alternative therapies when appropriate.

To order Mopetia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mopetia (paliperidone) is a metabolite of risperidone and shares a similar receptor profile, but its long‑acting injectable form provides more consistent plasma levels and improved adherence compared with many oral atypical antipsychotics. Compared with other injectables, it offers a convenient dosing interval and a well‑characterised safety profile.

Mopetia should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper handling during transport.

Mopetia is administered as an intramuscular injection by a qualified healthcare professional. The injection is typically given in the gluteal or deltoid muscle, following aseptic technique, and the dosing schedule is defined by the prescribing clinician.

The most serious adverse reactions to monitor include neuroleptic malignant syndrome (characterised by fever, rigidity, and autonomic instability), tardive dyskinesia (potentially irreversible involuntary movements), and seizures, especially at higher doses or in predisposed individuals.

Mopetia is contraindicated in patients with known hypersensitivity to paliperidone or any component of the formulation. It should also be avoided in individuals with severe central nervous system depression, uncontrolled cardiovascular conditions, or those taking medications that significantly prolong the QT interval without careful monitoring.